1. Home
  2. DSU vs PHAT Comparison

DSU vs PHAT Comparison

Compare DSU & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock Debt Strategies Fund Inc.

DSU

Blackrock Debt Strategies Fund Inc.

N/A

Current Price

$8.63

Market Cap

560.4M

Sector

Finance

ML Signal

N/A

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

N/A

Current Price

$5.85

Market Cap

590.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DSU
PHAT
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
560.4M
590.6M
IPO Year
1998
2019

Fundamental Metrics

Financial Performance
Metric
DSU
PHAT
Price
$8.63
$5.85
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $20.05
AVG Volume (30 Days)
396.9K
★ 1.7M
Earning Date
01-01-0001
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 42.72
EPS
★ N/A
N/A
Revenue
N/A
★ $175,110,000.00
Revenue This Year
N/A
$79.63
Revenue Next Year
N/A
$54.71
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 216.93
52 Week Low
$8.42
$5.02
52 Week High
$10.40
$18.31

Technical Indicators

Market Signals
Indicator
DSU
PHAT
Relative Strength Index (RSI) 40.20 34.30
Support Level $8.42 $5.02
Resistance Level $9.94 $7.72
Average True Range (ATR) 0.08 0.62
MACD 0.02 -0.06
Stochastic Oscillator 65.22 28.10

Price Performance

Historical Comparison
DSU
PHAT

About DSU Blackrock Debt Strategies Fund Inc.

Blackrock Debt Strategies Fund Inc is a closed-end management investment company. Its primary investment objective is to seek to provide current income by investing in a diversified portfolio of U.S. companies debt instruments, including senior and subordinated corporate loans, both secured and unsecured, which are rated in the lower rating categories of the established rating services or unrated debt instruments, which are in the judgment of the investment adviser of equivalent quality. The Fund may invest directly in debt instruments or synthetically through the use of derivatives. The Fund's secondary investment objective is to seek to provide capital appreciation.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: